<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app41.us.archive.org';v.server_ms=568;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-10252?contentType=xml', '20160930192852')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20160930192852/https://www.guideline.gov/summaries/downloadcontent/ngc-10252?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20160930192852/https://www.guideline.gov/summaries/downloadcontent/ngc-10252?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-10252?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20160930192852" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap">Aug</td>
		  <td class="c" id="displayMonthEl" title="You are here: 19:28:52 Sep 30, 2016">SEP</td>
		  <td class="f" nowrap="nowrap">Oct</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_prv_off.png" alt="Previous capture" width="14" height="16" border="0" /></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 19:28:52 Sep 30, 2016">30</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap">2015</td>
		  <td class="c" id="displayYearEl" title="You are here: 19:28:52 Sep 30, 2016">2016</td>
		  <td class="f" nowrap="nowrap">2017</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20160930192852*/https://www.guideline.gov/summaries/downloadcontent/ngc-10252?contentType=xml" title="See a list of every capture for this URL">1 capture</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Partner-593);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Partner-593" target="_new"><span class="wm-title">Government Printing Office</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  Archive-It Partner 593: Government Printing Office
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Collection-5265)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Collection-5265" target="_new"><span class="wm-title">National Guideline Clearinghouse</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ) External Web Site Policy, U.S. Department of Health and Human Services. NGC was originally created by AHRQ in partnership with the American Medical Association and the American Association of Health Plans (now America's Health Insurance Plans [AHIP]).

The NGC mission is to provide physicians and other health professionals, health care providers, health plans, integrated delivery systems, purchasers, and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-10252?contentType=xml","2016-09-30",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Endometrial cancer.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Alberta Provincial Gynecologic Oncology Tumour Team. Endometrial cancer. Edmonton (Alberta): CancerControl Alberta; 2013 Sep. 15 p.&amp;nbsp;(Clinical practice guideline; no. GYNE-002).&amp;nbsp; [76 references]</td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Alberta Provincial Gynecologic Oncology Tumour Team. Endometrial cancer. Edmonton (Alberta): Alberta Health Services, Cancer Care; 2012 Apr. 16 p. (Clinical practice guideline; no. GYNE-002).</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following recommendations were considered when developing the recommendations: National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), the British Columbia Cancer Agency (BCCA), and Cancer Care Ontario (CCO) as per F&amp;eacute;d&amp;eacute;ration Internationale de Gynecologie et d'Obst&amp;eacute;trique (FIGO) Staging (2010). A detailed description of this staging system can be found in the Appendix of the original guideline document.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Surgery</span></strong></p>
<p>A pathology review should be performed by a pathologist with experience in gynecologic pathology.</p>
<p>As the majority of patients is diagnosed with adenocarcinomas and is diagnosed in early stage, the standard treatment is a hysterectomy with bilateral salpingo-oophorectomy (BSO) with or without lymph node dissection. Patients should be referred to the gynecologic oncologists at the Cross Cancer Institute, Edmonton or the Tom Baker Cancer Centre, Calgary if the adenocarcinoma is grade II or greater and if it is a clinical stage II or greater.</p>
<p>Papillary serous, clear cell carcinomas, and carcinosarcomas of the uterus require a comprehensive staging procedure which includes a hysterectomy, BSO, pelvic and para-aortic lymph node dissection, and an omentectomy (Gien et al., 2007). These patients also need referral to the gynecologic oncologists.</p>
<p>For clinically obvious cervix involvement, referral to the cancer centre is warranted for consideration of a radical hysterectomy, BSO with lymphadenectomy, OR preoperative radiotherapy followed by a simple hysterectomy with BSO. For <em><strong>medically unfit patients</strong></em>, where surgery is not an option, treatment may include radiotherapy alone or with hormonal therapy and/or chemotherapy.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Adjuvant Treatment for Completely Surgically Staged Adenocarcinoma (as per FIGO, 2010)</span></strong></p>
<p><strong>Stage IA</strong></p>
<p>The majority (70%) of patients will present with a grade 1 or 2 tumour, while about 30% will present with a grade 3 tumour. Treatment can vary, depending on the presence of adverse risk factors. These include positive lymphovascular invasion, tumour size, and cervical glandular involvement and age &amp;gt;65 years.</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Grade 1: observe/no adjuvant treatment </li>
    <li>Grade 2: observe/no adjuvant treatment or vaginal vault brachytherapy can be considered if patient has lymphovascular space involvement (LVSI) or based on patient age </li>
    <li>Grade 3: vaginal brachytherapy if adverse risk factors are present (30% of stage 1A grade 3 patients) </li>
    <li>OR if patient has LVSI, consider enrolment in PORTEC-3/EN.7 Trial </li>
</ul>
<p><strong>Stage IB</strong></p>
<p>Approximately 35% of all patients with endometrial cancer will present with a stage IB.</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Grade 1: vaginal vault brachytherapy can be offered </li>
    <li>Grade 2: vaginal vault brachytherapy </li>
    <li>Grade 3: whole pelvic radiation therapy or vaginal vault brachytherapy (consideration of chemotherapy to be discussed in a multidisciplinary setting) </li>
    <li>OR consider enrolment in PORTEC-3/EN.7 Trial </li>
</ul>
<p><strong>Stage II</strong></p>
<p>Approximately 10% of all patients with endometrial cancer will present with a stage II tumour. For clinically obvious cervix involvement, consider a radical hysterectomy, BSO with lymphadenectomy, OR preoperative radiotherapy followed by a simple hysterectomy with BSO. In the case of stage II disease where pre-operative radiotherapy is given, intracavitary radiotherapy is usually given in addition to external beam radiotherapy (EBRT).</p>
<p>Postoperative management:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Grade 1: Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Observe/no treatment if radical hysterectomy, BSO, and pelvic lymphadenectomy done; otherwise, treat with pelvic radiotherapy plus vaginal brachytherapy </li>
        <li>OR consider enrolment in PORTEC-3/EN.7 Trial (macroscopic stage II for which radical hysterectomy has been carried out are excluded) </li>
    </ul>
    </li>
    <li>Grade 2: Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Treat with pelvic radiotherapy plus vaginal brachytherapy </li>
        <li>OR consider enrolment in PORTEC-3/EN.7 Trial (macroscopic stage II for which radical hysterectomy has been carried out are excluded) </li>
    </ul>
    </li>
    <li>Grade 3: Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Treat with pelvic radiotherapy plus vaginal brachytherapy </li>
        <li>OR consider enrolment in PORTEC-3/EN.7 Trial (macroscopic stage II for which radical hysterectomy has been carried out are excluded) </li>
    </ul>
    </li>
</ul>
<p><strong>Stage III</strong></p>
<p>Approximately 20% of all patients with endometrial cancer will present with a stage III tumour.</p>
<p><em>Stages IIIA and IIIB</em></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Grades 1/2/3: Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Chemotherapy +/- radiotherapy +/- hormone therapy </li>
        <li>OR Adjuvant radiotherapy +/- chemotherapy +/- hormone therapy </li>
        <li>OR Pelvic radiotherapy +/- vaginal brachytherapy </li>
        <li>OR enrolment in PORTEC-3/EN.7 Trial </li>
    </ul>
    </li>
</ul>
<p><em>Stages IIIC1 and IIIC2</em></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Grades 1/2/3: Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Chemotherapy +/- EBRT +/- vaginal brachytherapy +/- hormone therapy </li>
        <li>OR enrolment in PORTEC-3/EN.7 Trial </li>
    </ul>
    </li>
</ul>
<p><strong>Stage IV</strong></p>
<p>Approximately 10% of all patients with endometrial cancer will present with a stage IV tumour.</p>
<p><em>Stage IVA</em></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Chemotherapy +/- hormone therapy +/- pelvic EBRT </li>
        <li>Participation in clinical trials is strongly encouraged </li>
    </ul>
    </li>
</ul>
<p><em>Stage IVB</em></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Chemotherapy +/- hormone therapy +/- consideration of palliative radiotherapy </li>
        <li>Participation in clinical trials is strongly encouraged </li>
    </ul>
    </li>
</ul>
<p>Positive cytology (for completely staged patients with no other extrauterine disease)</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Grades 1/2/3: Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Observe or consider vaginal brachytherapy or pelvic radiotherapy (RT) +/- vaginal brachytherapy +/- chemotherapy if there are other prognostic factors </li>
        <li>OR enrolment in PORTEC-3/EN.7 Trial </li>
    </ul>
    </li>
</ul>
<p><strong>Recommended Chemotherapy</strong></p>
<p>Four to six cycles of carboplatin (area under the curve [AUC] 5) with paclitaxel at 175 mg/m<sup>2</sup>. In the case of hypersensitivity to paclitaxel, docetaxel at 75 mg/m<sup>2</sup> should be considered.</p>
<p><strong>Recommended Hormone Therapy</strong></p>
<p>The recommended medications are medroxyprogesterone (Provera) 200&amp;ndash;400 mg daily or Megestrol (Megace) 160 mg daily.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Adjuvant Treatment for Surgically Staged Papillary Serous and Clear Cell Carcinomas</span></strong></p>
<p><strong>Stage IA</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Observe if there is no myometrial invasion +/- vaginal brachytherapy for grade 3 </li>
        <li>OR chemotherapy +/- vaginal brachytherapy if there is myometrial invasion </li>
        <li>OR enrolment in PORTEC-3/EN.7 Trial </li>
    </ul>
    </li>
</ul>
<p><strong>Stage IB, Stage II</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Chemotherapy +/- RT </li>
        <li>OR enrolment in PORTEC-3/EN.7 Trial </li>
    </ul>
    </li>
</ul>
<p><strong>Stage III, Stage IV (Adequately Debulked)</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Chemotherapy +/- RT </li>
        <li>OR enrolment in PORTEC-3/EN.7 Trial (only eligible if microscopic residual disease) </li>
    </ul>
    </li>
</ul>
<p><strong>Recommended Chemotherapy</strong></p>
<p>Four to six cycles of carboplatin (AUC 5) with paclitaxel at 175 mg/m<sup>2</sup>. In the case of hypersensitivity to paclitaxel, docetaxel at 75 mg/m<sup>2</sup> should be considered.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Adjuvant Treatment for Incompletely Surgically Staged Patients</span></strong></p>
<p>A computed tomography (CT) scan of the chest, abdomen and pelvis is recommended.</p>
<p>Consider reoperating for surgical staging.</p>
<p><strong>Stage IB</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Grades 1/2: Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>If radiologic imaging is negative, treat with vaginal brachytherapy +/- pelvic radiotherapy </li>
        <li>If radiologic imaging is positive, surgically restage and then treat as for completely surgically staged patients (as above) </li>
    </ul>
    </li>
    <li>Grade 3: Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>If radiologic imaging is negative, treat with pelvic radiotherapy and vaginal brachytherapy +/- para-aortic radiotherapy. For grade 3 tumours, chemotherapy may be added </li>
        <li>If radiologic imaging is positive, consider surgical restaging; treat with pelvic radiotherapy +/- vaginal brachytherapy </li>
        <li>OR if patient has LVSI, consider enrolment in PORTEC-3/EN.7 Trial </li>
    </ul>
    </li>
</ul>
<p><strong>Stage II</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Options include:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>If radiologic imaging is negative, treat with pelvic radiotherapy and vaginal brachytherapy +/- para-aortic radiotherapy. For grade 3 tumours, chemotherapy may be added </li>
        <li>If radiologic imaging is positive, treat with pelvic radiotherapy +/- vaginal brachytherapy +/- chemotherapy </li>
        <li>OR consider enrolment in PORTEC-3/EN.7 Trial </li>
    </ul>
    </li>
</ul>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Therapy for Relapsed Patients</span></strong></p>
<p>The recurrence rate for endometrial cancer is approximately 20%. The majority (70%) of recurrences will be confined to the pelvis, while the remaining (30%) will be extrapelvic recurrences.</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Consider enrolment in a clinical trial. </li>
    <li>For pelvic recurrences, if no prior radiotherapy has been given to site of recurrence, then treat with EBRT plus brachytherapy or surgical exploration of the pelvis plus resection, with post-operative radiation therapy (PORT). </li>
    <li>For extrapelvic recurrences, treat with chemotherapy +/- hormone therapy +/- radiotherapy; if prior radiotherapy has been given to the site of recurrence, one of the following can be considered:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Surgical exploration of the pelvis plus resection, with or without PORT </li>
        <li>Hormone therapy </li>
        <li>Chemotherapy </li>
    </ul>
    </li>
    <li>For isolated metastases, consider resection with or without radiotherapy. If the tumour is unresectable or if there is further recurrence, then treat as disseminated metastases (see below). </li>
    <li>For disseminated metastases, if asymptomatic or low grade, then treat with hormone therapy then chemotherapy. If symptomatic or grade 2/3, or large volume, the treat with chemotherapy and/or palliative radiotherapy. </li>
</ul>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Follow-up and Surveillance</span></strong></p>
<p>The following suggestions for follow-up of women without evidence of disease after primary potentially curative treatment for any stage of endometrial cancer have been modified from the American College of Obstetricians and Gynecologists (2005) and Cancer Care Ontario (2006) follow-up guidelines (see the &quot;Adaptation&quot; field):</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Patient counseling on potential recurrence symptoms could include discussion of:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Unexplained vaginal bleeding or discharge </li>
        <li>Detection of a mass </li>
        <li>Abdominal distension </li>
        <li>Persistent pain, especially in the abdomen or pelvic region </li>
        <li>Fatigue </li>
        <li>Diarrhea, nausea or vomiting </li>
        <li>Persistent cough </li>
        <li>Swelling </li>
        <li>Weight loss </li>
    </ul>
    </li>
    <li>Follow-up by the treating gynecologic oncologist, general gynecologist, or general practitioner could be based on the risk of recurrence. The majority of recurrences are symptomatic and occur within 5 years.
    <p>A general examination, including complete history, speculum, and a pelvic-rectal examination, could be performed as follows:</p>
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Low-risk patients (i.e., stage IA or IB, grade 1 or 2): every 6 months during years 1 through 3, then once yearly during years 4 and 5. </li>
        <li>High-risk patients (i.e., stage IA or IB, grade 3, or stage IC or advanced stage): every 3 to 6 months during years 1 through 3, then every 6 months during years 4 and 5. </li>
    </ul>
    </li>
    <li>Patients who are symptomatic should undergo appropriate investigations to rule out recurrence, as many local recurrences are potentially curable with additional therapy. </li>
</ul></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Endometrial cancer</p>
<p class=&quot;Note&quot;><strong>Note</strong>: There are several histological types of endometrial cancer. These include endometrioid and variants, such as ciliated cell adenocarcinoma, secretory adenocarcinoma, villoglandular, and adenocarcinoma with squamous differentiation, accounting for 75% to 80%; mixed, accounting for 10%; uterine papillary serous, accounting for &amp;lt;10%; clear cell, accounting for 4%; mucinous, accounting for 1%; squamous cell, accounting for &amp;lt;1%; and undifferentiated.</p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Evaluation"/>
      <fieldvalue value="Management"/>
      <fieldvalue value="Treatment"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Obstetrics and Gynecology"/>
      <fieldvalue value="Oncology"/>
      <fieldvalue value="Pathology"/>
      <fieldvalue value="Radiation Oncology"/>
      <fieldvalue value="Surgery"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Advanced Practice Nurses"/>
      <fieldvalue value="Nurses"/>
      <fieldvalue value="Physician Assistants"/>
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To review endometrial cancer treatment options including surgery, radiotherapy, chemotherapy and hormone therapy</p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Women with endometrial cancer, including uterine carcinosarcoma</p>
<p class=&quot;Note&quot;><strong>Note</strong>: This guideline does not cover leiomyosarcoma and endometrial stromal sarcoma, which should be staged as uterine sarcomas. For recommendations on the management of uterine sarcomas, please refer to the National Guideline Clearinghouse (NGC) summary of the Alberta Health Services guideline <a href=&quot;/content.aspx?id=47854&quot; title=&quot;Guideline #10272&quot;>Uterine sarcoma</a>.</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<ol style=&quot;list-style-type: decimal;&quot;>
    <li>Surgery with pathology review
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Hysterectomy with bilateral salpingo-oophorectomy (BSO), lymph node dissection, and omentectomy </li>
        <li>Preoperative radiotherapy </li>
        <li>Referral to gynecologic oncologist </li>
    </ul>
    </li>
    <li>Adjuvant treatment/management
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Observation or no treatment </li>
        <li>Pelvic radiotherapy </li>
        <li>Vaginal vault brachytherapy </li>
        <li>Whole pelvic radiation </li>
        <li>Para-aortic radiotherapy </li>
        <li>Enrolment in PORTEC-3/EN.7 trial </li>
        <li>Hormone therapy (medroxyprogesterone, megestrol) </li>
        <li>Chemotherapy (carboplatin, paclitaxel, docetaxel) </li>
        <li>External beam radiotherapy (EBRT) </li>
        <li>Palliative radiotherapy </li>
        <li>Computed tomography (CT) scan of chest, abdomen, pelvis </li>
        <li>Reoperation for surgical staging </li>
    </ul>
    </li>
    <li>Therapy for relapses
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Enrolment in a clinical trial </li>
        <li>EBRT plus brachytherapy </li>
        <li>Surgical exploration of the pelvis plus resection with or without post-operative radiation therapy </li>
        <li>Hormone therapy </li>
        <li>Chemotherapy </li>
        <li>Palliative radiotherapy </li>
    </ul>
    </li>
    <li>Follow-up and surveillance
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Counseling patient about potential recurrence symptoms </li>
        <li>Follow-up examinations based on risk of recurrence </li>
    </ul>
    </li>
</ol>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Recurrence </li>
    <li>5-year progression-free survival </li>
    <li>5-year overall survival </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Searches of Electronic Databases"/>
      <fieldvalue value="Searches of Unpublished Data"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Research Questions</strong></p>
<p>Specific research questions to be addressed by the guideline document were formulated by the guideline lead(s) and Knowledge Management (KM) Specialist using the PICO question format (Patient or Population, Intervention, Comparisons, Outcomes).</p>
<p><strong>Guideline Questions</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Is chemotherapy following surgery in women diagnosed with endometrial cancer, at various stages and grade classifications more effective than surgery alone in preventing recurrence and/or improving progression free survival? </li>
    <li>Is radiation therapy following surgery in women diagnosed with endometrial cancer, at various stages and grade classifications more effective than surgery alone in preventing recurrence and/or improving progression free survival? </li>
    <li>Is hormone therapy following surgery in women diagnosed with endometrial cancer, at various stages and grade classifications more effective than surgery alone in preventing recurrence and/or improving progression free survival? </li>
</ul>
<p><strong>Search Strategy</strong></p>
<p>Entries to the Medline, EMBASE, and Cochrane databases and clinical practice guideline databases were searched for evidence relevant to this topic. Search terms included: endometrial OR endometrium AND cancer OR carcinoma OR adenocarcinoma OR carcinosarcoma AND (1) chemotherapy OR carboplatin OR Taxol; or (2) brachytherapy OR radiotherapy OR radiation; or (3) progestogens OR megestrol OR Megace OR hormone; or (4) oophorectomy OR lymphadenectomy OR hysterectomy OR surgery.</p>
<p>Guidelines reviewed include the following: the National Comprehensive Cancer Network (NCCN) guidelines (2013), the European Society for Medical Oncology (ESMO) guidelines (2013), the BC Cancer Agency (BCCA) guidelines (2011), and Cancer Care Ontario (CCO) Program in Evidence-Based Care guidelines (2006&amp;ndash;2007). All randomized controlled trials on the role of chemotherapy were reviewed from 1997 through to February 2011. The PORTEC-3/EN.7 trial was also reviewed.</p>
<p>The guideline was originally developed in 2009 and then updated in 2011, 2012, and again in 2013. The literature was reviewed prior to each update, using the search strategy described above.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>A total of 46 studies were included through the 2011 review. </li>
    <li>The 2012 and 2013 reviews included a total of 13 studies and 11 studies, respectively. </li>
</ul>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Not stated"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Review of Published Meta-Analyses"/>
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Evidence was selected and reviewed by a working group comprised of members from the Alberta Provincial Gynecologic Oncology Tumour Team and a Knowledge Management (KM) Specialist from the Guideline Utilization Resource Unit (GURU). A detailed description of the methodology followed during the guideline development process can be found in the <a href=&quot;http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-utilization-handbook.pdf&quot; title=&quot;Alberta Health Services Web site&quot;>Guideline Utilization Resource Unit Handbook</a> (see the &quot;Availability of Companion Documents&quot; field).</p>
<p><strong>Evidence Tables</strong></p>
<p>Evidence tables containing the first author, year of publication, patient group/stage of disease, methodology, and main outcomes of interest are assembled using the studies identified in the literature search. Existing guidelines on the topic are assessed by the KM Specialist using portions of the Appraisal of Guidelines Research and Evaluation (AGREE) II instrument (<a href=&quot;http://www.agreetrust.org&quot; title=&quot;AGREE Trust Web site&quot;>http://www.agreetrust.org</a>) and those meeting the minimum requirements are included in the evidence document. Due to limited resources, GURU does not regularly employ the use of multiple reviewers to rank the level of evidence; rather, the methodology portion of the evidence table contains the pertinent information required for the reader to judge for himself the quality of the studies.</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Formulating Recommendations</strong></p>
<p>The working group members formulated the guideline recommendations based on the evidence synthesized by the Knowledge Management (KM) Specialist during the planning process, blended with expert clinical interpretation of the evidence. As detailed in the <a href=&quot;http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-utilization-handbook.pdf&quot; title=&quot;Alberta Health Services Web site&quot;>Guideline Utilization Resource Unit Handbook</a> (see the &quot;Availability of Companion Documents&quot; field), the working group members may decide to adopt the recommendations of another institution without any revisions, adapt the recommendations of another institution or institutions to better reflect local practices, or develop their own set of recommendations by adapting some, but not all, recommendations from different guidelines.</p>
<p>The degree to which a recommendation is based on expert opinion of the working group and/or the Provincial Tumour Team members is explicitly stated in the guideline recommendations. Similar to the American Society of Clinical Oncology (ASCO) methodology for formulating guideline recommendations, the Guideline Utilization Resource Unit (GURU) does not use formal rating schemes for describing the strength of the recommendations, but rather describes, in conventional and explicit language, the type and quality of the research and existing guidelines that were taken into consideration when formulating the recommendations.</p>
<p>Following a review of the evidence by the Alberta Provincial Gynecologic Oncology Team, no major changes were made to the recommendations and the guideline was reaffirmed.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="Internal Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This guideline was reviewed and endorsed by the Alberta Provincial Gynecologic Oncology Tumour Team.</p>
<p>When the draft guideline document has been completed, revised, and reviewed by the Knowledge Management (KM) Specialist and the working group members, it is sent to all members of the Provincial Tumour Team for review and comment. This step ensures that those intended to use the guideline have the opportunity to review the document and identify potential difficulties for implementation before the guideline is finalized. Depending on the size of the document, and the number of people it is sent to for review, a deadline of one to two weeks will usually be given to submit any feedback. Ideally, this review will occur prior to the annual Provincial Tumour Team meeting, and a discussion of the proposed edits will take place at the meeting. The working group members will then make final revisions to the document based on the received feedback, as appropriate. Once the guideline is finalized, it will be officially endorsed by the Provincial Tumour Team Lead and the Executive Director of Provincial Tumour Programs.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="98" ordby="605" id="425" name="References Supporting the Recommendations" type="citation">
      <fieldvalue value="<table><tr><td>Gien L, Kwon J, Oliver T, Fung-Kee-Fung M, Gynecology Cancer Disease Site Group. Adjuvant hormonal therapy for stage 1 endometrial cancer: recommendations. Toronto (ON): Cancer Care Ontario (CCO); 2007 Oct 25. 19 p.&amp;nbsp;(Evidence-based series; no. 4-14).&amp;nbsp; [18 references]</td></tr></table>"/>
    </field>
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The recommendations are partially adapted from existing guidance (see the &quot;Adaptation&quot; field).</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Appropriate management and evidence-based care of women with endometrial cancer </li>
    <li>Prevention of recurrence and improved survival </li>
</ul>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Chemotherapy-related toxicity</p></div>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The recommendations contained in this guideline are a consensus of the Alberta Provincial Gynecologic Oncology Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.</p></div>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Present the guideline at the local and provincial tumour team meetings and weekly rounds. </li>
    <li>Post the guideline on the Alberta Health Services website. </li>
    <li>Send an electronic notification of the new guideline to all members of CancerControl Alberta. </li>
</ul>"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="End of Life Care"/>
      <fieldvalue value="Getting Better"/>
      <fieldvalue value="Living with Illness"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Alberta Provincial Gynecologic Oncology Tumour Team. Endometrial cancer. Edmonton (Alberta): CancerControl Alberta; 2013 Sep. 15 p.&amp;nbsp;(Clinical practice guideline; no. GYNE-002).&amp;nbsp; [76 references]</td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The recommendations on follow-up and surveillance are modified from the following guidelines:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin, Clinical Management guidelines for obstetrician-gynecologists. Number 65, August 2005. </li>
    <li>Fung-Kee-Fung M, Dodge J, Elit L, et al., and the Gynecology Cancer Disease Site Group. Follow-up after Primary Therapy for Endometrial Cancer: A Clinical Practice Guideline. Program in Evidence-Based Care, Cancer Care Ontario. Evidence-based Series #4-9: Section 1; Report Date: January 10, 2006. </li>
</ul></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2012 Apr (revised 2013 Sep)"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="CancerControl Alberta - State/Local Government Agency [Non-U.S.]"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>CancerControl Alberta</p>
<p>There was no direct industry involvement in the development or dissemination of this guideline.</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Alberta Provincial Gynecologic Oncology Tumour Team</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Members of the Alberta Provincial Gynecologic Oncology Tumour Team include gynecologic oncologists, radiation oncologists, medical oncologists, pathologists, nurses, and pharmacists.</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Participation of members of the Alberta Provincial Gynecologic Oncology Team in the development of this guideline has been voluntary and the authors have not been remunerated for their contributions. CancerControl Alberta recognizes that although industry support of research, education and other areas is necessary in order to advance patient care, such support may lead to potential conflicts of interest. Some members of the Alberta Provincial Gynecologic Oncology Team are involved in research funded by industry or have other such potential conflicts of interest. However the developers of this guideline are satisfied it was developed in an unbiased manner.</p></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Alberta Provincial Gynecologic Oncology Tumour Team. Endometrial cancer. Edmonton (Alberta): Alberta Health Services, Cancer Care; 2012 Apr. 16 p. (Clinical practice guideline; no. GYNE-002).</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Electronic copies: Available in Portable Document Format (PDF) from the <a href=&quot;http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-gyne002-endometrial.pdf&quot; title=&quot;Alberta Health Services Web site&quot;>Alberta Health Services Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following is available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Guideline utilization resource unit handbook. Edmonton (Alberta): CancerControl Alberta; 2013 Jan. 5 p. Electronic copies: Available in Portable Document Format (PDF) from the <a href=&quot;http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-utilization-handbook.pdf&quot; title=&quot;Alberta Health Services Web site&quot;>Alberta Health Services Web site</a>. </li>
</ul></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on December 6, 2012. The information was verified by the guideline developer on January 14, 2013. This summary was updated by ECRI Institute on April 28, 2014. The updated information was verified by the guideline developer on May 22, 2014. This summary was updated by ECRI Institute on July 18, 2014 following the U.S. Food and Drug Administration advisory on Docetaxel.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <a href=&quot;/about/inclusion-criteria.aspx&quot;>http://www.guideline.gov/about/inclusion-criteria.aspx</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 19:28:52 Sep 30, 2016 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 00:25:25 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 70.899 (3)
  esindex: 0.007
  captures_list: 92.357
  CDXLines.iter: 15.812 (3)
  PetaboxLoader3.datanode: 80.036 (4)
  exclusion.robots: 0.293
  exclusion.robots.policy: 0.28
  RedisCDXSource: 1.788
  PetaboxLoader3.resolve: 435.527
  load_resource: 449.909
-->